Investigation Launched into Catamaran Corporation's Sale to OptumRx

Strategic Insights -

Johnson & Weaver, LLP, a leading shareholder rights law firm, has initiated an investigation into Catamaran Corporation's proposed sale to OptumRx, a subsidiary of UnitedHealth Group. The investigation focuses on whether Catamaran's board members have fulfilled their fiduciary duties to shareholders by ensuring the best possible price for the company's shares. With a $66.00 price target from a Wall Street analyst surpassing the proposed $61.50 offer, there are concerns that the acquisition price may be inadequate, given Catamaran's predicted future growth. Shareholders who believe the proposed buyout price is too low or are interested in learning more about the investigation can contact lead analyst Jim Baker at 619-814-4471 or jimb@johnsonandweaver.com.

Key Takeaways:

  • Johnson & Weaver, LLP is investigating whether Catamaran's board members failed to satisfy their fiduciary duties to the company's shareholders.
  • The proposed sale of Catamaran to OptumRx, priced at $61.50 per share, has raised concerns about the adequacy of the offer price, given the company's predicted future growth.
  • A Wall Street analyst has set a price target of $66.00 per share, which is more than the proposed offer price.
  • The investigation will examine whether the board adequately pursued alternatives to the acquisition and obtained the best possible price for the company's shares of common stock.
  • Johnson & Weaver, LLP represents individual and institutional investors in shareholder derivative and securities class action lawsuits.
  • Attorney advertising. Past results do not guarantee future outcomes.

Statistics:

  • Proposed sale price: $61.50 per share.
  • Price target set by Wall Street analyst: $66.00 per share.
  • Acquisition of Catamaran to be completed by OptumRx.
  • Number of employees at OptumRx: Not mentioned in the source material.

Sources:

  • Johnson & Weaver, LLP (http://www.johnsonandweaver.com)
  • Press release announcing the investigation into Catamaran Corporation's sale to OptumRx.